Acalabrutinib

ApprovedRecruiting

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Chronic Lymphocytic Leukaemia

Conditions

Chronic Lymphocytic Leukaemia, Heart Failure

Trial Timeline

Feb 4, 2025 → Aug 16, 2030

NCT ID

NCT06651970

About Acalabrutinib

Acalabrutinib is a approved stage product being developed by AstraZeneca for Chronic Lymphocytic Leukaemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06651970. Target conditions include Chronic Lymphocytic Leukaemia, Heart Failure.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06757647	Phase 2	Recruiting	May 27, 2025	Dec 31, 2027	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06651970	Approved	Recruiting	Feb 4, 2025	Aug 16, 2030	Chronic Lymphocytic Leukaemia
NCT06205498	Pre-clinical	Active	Aug 8, 2023	Apr 30, 2027	Chronic Lymphocytic Leukemia
NCT05256641	Phase 1/2	Recruiting	Jan 23, 2023	Jan 31, 2028	Diffuse Large B-Cell Lymphoma
NCT05557695	Pre-clinical	Recruiting	Oct 17, 2022	Apr 1, 2027	Chronic Lymphocytic Leukemia, CLL
NCT04660045	Phase 2	Withdrawn	May 1, 2022	Jun 1, 2026	Chronic Lymphocytic Leukemia
NCT05038904	Phase 2	Completed	Dec 16, 2021	Dec 31, 2022	Food Allergy
NCT04198922	Phase 2	Active	Dec 11, 2020	Apr 30, 2027	Recurrent Moderate-Severe Chronic Graft Versus Host Disease
NCT04548648	Phase 2	Active	Oct 15, 2020	Mar 14, 2030	Central Nervous System Lymphoma
NCT04497948	Phase 1	Terminated	Sep 21, 2020	Nov 18, 2020	COVID-19
NCT04380688	Phase 2	Completed	Jun 13, 2020	Nov 16, 2020	COVID-19
NCT04346199	Phase 2	Completed	Jun 12, 2020	Nov 17, 2020	COVID-19
NCT03932331	Phase 1/2	Active	Apr 29, 2020	Jun 24, 2026	Phase I: Relapsed or Refractory B-cell Malignancies
NCT04008706	Phase 3	Completed	Sep 17, 2019	Nov 4, 2025	Chronic Lymphocytic Leukemia
NCT03968848	Phase 1	Completed	Nov 12, 2018	Mar 29, 2019	Hepatic Impairment

Competing Products

20 competing products in Chronic Lymphocytic Leukaemia

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved